Search research articles
Contact Us
Filters
Showing results (271-280 of 304) with videos related to
Page
of 31
Sort By:
Plos Genetics
|
April 11, 2022
Tumor suppressor PALB2 maintains redox and mitochondrial homeostasis in the brain and cooperates with ATG7/autophagy to suppress neurodegeneration
Yanying Huo, Akshada Sawant, Yongmei Tan, et al.
Leukemia
|
April 9, 2010
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms
O Kosmider, V Gelsi-Boyer, L Slama, et al.
Leukemia
|
June 13, 2008
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
S Park, N Chapuis, V Bardet, et al.
Leukemia
|
April 16, 2011
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
R Itzykson, O Kosmider, T Cluzeau, et al.
Leukemia
|
September 26, 1997
Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphoblastic Leukemia
A Delannoy, C Sebban, P Cony-Makhoul, et al.
Leukemia Research
|
August 2, 2011
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS
S Park, R Sapena, C Kelaidi, et al.
Leukemia
|
April 24, 1999
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes
E Wattel, E Solary, X Leleu, et al.
British Journal of Haematology
|
May 10, 2006
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study
L Mannone, C Gardin, M C Quarre, et al.
Leukemia Research
|
December 20, 2011
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
R Itzykson, S Thépot, O Beyne-Rauzy, et al.
Leukemia
|
November 9, 2011
SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications
F Damm, F Thol, O Kosmider, et al.
Page
of 31
Search research articles
Search
Showing results (271-280 of 304) with videos related to
Sort By:
Page
of 31
Plos Genetics
|
April 11, 2022
Tumor suppressor PALB2 maintains redox and mitochondrial homeostasis in the brain and cooperates with ATG7/autophagy to suppress neurodegeneration
Yanying Huo, Akshada Sawant, Yongmei Tan, et al.
Leukemia
|
April 9, 2010
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms
O Kosmider, V Gelsi-Boyer, L Slama, et al.
Leukemia
|
June 13, 2008
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
S Park, N Chapuis, V Bardet, et al.
Leukemia
|
April 16, 2011
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
R Itzykson, O Kosmider, T Cluzeau, et al.
Leukemia
|
September 26, 1997
Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphoblastic Leukemia
A Delannoy, C Sebban, P Cony-Makhoul, et al.
Leukemia Research
|
August 2, 2011
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS
S Park, R Sapena, C Kelaidi, et al.
Leukemia
|
April 24, 1999
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes
E Wattel, E Solary, X Leleu, et al.
British Journal of Haematology
|
May 10, 2006
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study
L Mannone, C Gardin, M C Quarre, et al.
Leukemia Research
|
December 20, 2011
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
R Itzykson, S Thépot, O Beyne-Rauzy, et al.
Leukemia
|
November 9, 2011
SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications
F Damm, F Thol, O Kosmider, et al.
Page
of 31